Alip Borthakur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alip Borthakur has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
Anoop Kumar
Division of Gastroenterology and Hepatology, Department of Medicine University of Illinois at Chicago Chicago Illinois USA
15 shared publications- Pradeep K. Dudeja
Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA
14 shared publications Pradeep K. Dudeja
Division of Gastroenterology and Hepatology, Department of Medicine University of Illinois at Chicago Chicago Illinois USA
12 shared publicationsWaddah A. Alrefai
Division of Gastroenterology and Hepatology, Department of Medicine University of Illinois at Chicago Chicago Illinois USA
11 shared publicationsArivarasu N. Anbazhagan
Division of Gastroenterology and Hepatology, Department of Medicine University of Illinois at Chicago Chicago Illinois USA
8 shared publicationsSumit Bhattacharyya
Department of Medicine, Division of Gastroenterology & Hepatology, University of Illinois at Chicago, Chicago, Illinois; and
8 shared publications
Latest Publications
- 5 November 2026
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 483 (12) , 2327-2342
Beyond the gut: neuroinflammation as a driver of anxiety and depression in inflammatory bowel disease
Anxiety and depression frequently co-occur with inflammatory bowel disease (IBD), with prevalence rates substantially higher than in the general population. Emerging evidence further indicates that active IBD is associated with more severe psychological symptoms, while anxiety and depression can worsen intestinal inflammation, highlighting a bidirectional relationship. Chronic intestinal inflammation is increasingly recognized as a driver of neuroinflammation, a key mechanism underlying mood disorders. In IBD, disruption of the intestinal epithelial barrier permits metabolites and enteric signaling molecules to enter the circulation, triggering systemic inflammation and crossing the more permeable blood–brain barrier (BBB) to promote neuroinflammation. Other relevant components of the gut–brain axis contributing to IBD-associated neuroinflammation include the enteric nervous system, vagus nerve (VN), hypothalamic–pituitary–adrenal (HPA) axis, and tryptophan-kynurenine metabolism. Within the brain, neuroinflammation characterized by glial activation, inflammatory mediator release, and oxidative stress disrupts neurogenesis and synaptic plasticity in regions such as the hippocampus and prefrontal cortex, contributing to anxiety and depression. Conversely, anxiety and depression can amplify systemic inflammation through dysregulation of the VN and HPA axis, thereby exacerbating IBD. This reciprocal interaction adversely affects disease severity, quality of life, and therapeutic outcomes, underscoring the need to better define its underlying mechanisms. The present review synthesizes current clinical, translational, and experimental evidence on the bidirectional crosstalk between IBD and mood disorders. We also highlight key knowledge gaps, future research directions to identify the cellular and molecular mediators of this interaction, and emerging therapeutic strategies for the integrated management of both conditions.
- 5 November 2026
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 483 (12) , 2327-2342
Beyond the gut: neuroinflammation as a driver of anxiety and depression in inflammatory bowel disease
Anxiety and depression frequently co-occur with inflammatory bowel disease (IBD), with prevalence rates substantially higher than in the general population. Emerging evidence further indicates that active IBD is associated with more severe psychological symptoms, while anxiety and depression can worsen intestinal inflammation, highlighting a bidirectional relationship. Chronic intestinal inflammation is increasingly recognized as a driver of neuroinflammation, a key mechanism underlying mood disorders. In IBD, disruption of the intestinal epithelial barrier permits metabolites and enteric signaling molecules to enter the circulation, triggering systemic inflammation and crossing the more permeable blood–brain barrier (BBB) to promote neuroinflammation. Other relevant components of the gut–brain axis contributing to IBD-associated neuroinflammation include the enteric nervous system, vagus nerve (VN), hypothalamic–pituitary–adrenal (HPA) axis, and tryptophan-kynurenine metabolism. Within the brain, neuroinflammation characterized by glial activation, inflammatory mediator release, and oxidative stress disrupts neurogenesis and synaptic plasticity in regions such as the hippocampus and prefrontal cortex, contributing to anxiety and depression. Conversely, anxiety and depression can amplify systemic inflammation through dysregulation of the VN and HPA axis, thereby exacerbating IBD. This reciprocal interaction adversely affects disease severity, quality of life, and therapeutic outcomes, underscoring the need to better define its underlying mechanisms. The present review synthesizes current clinical, translational, and experimental evidence on the bidirectional crosstalk between IBD and mood disorders. We also highlight key knowledge gaps, future research directions to identify the cellular and molecular mediators of this interaction, and emerging therapeutic strategies for the integrated management of both conditions.
- Open Access
- 1 September 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (9) , 896
Hyperglycemic Adipocyte-Derived Exosomes Cause Oxidative Stress and Lipid Peroxidation in Brain Microvascular Endothelial Cells
Background/Aims: Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia and is a risk factor for stroke. Our previous studies demonstrated that adipocyte-derived exosomes (Ad-EXs) mediate adipose–brain communication. This study investigated the effects of hyperglycemic subcutaneous and visceral Ad-EXs on brain microvascular endothelial cell (BMEC) dysfunction during ischemic injury. Hypothesis: Hyperglycemic Ad-EXs exacerbate stroke injury via inducing oxidative stress and lipid peroxidation in BMECs. Methods: EXs were isolated from primary human subcutaneous and visceral adipocytes cultured in normal glucose (NG): NG-S-Ad-EXs and NG-V-Ad-EXs, or high-glucose (HG, 25 mM) media: HG-S-Ad-EXs and HG-V-Ad-EXs by ultracentrifugation and characterized by a nanoparticle tracking analysis system. PKH26-labeled Ad-EXs were used to evaluate uptake mechanisms in human BMECs (HBMECs). Functional effects were assessed in hypoxia/reoxygenation (H/R)-injured HBMECs treated with different Ad-EXs. Oxidative stress and lipid peroxidation markers (NOX2/4, MDA, 4-HNE, and GPX4) were analyzed. Results: HG increased Ad-EX release from both adipocyte depots. HG-derived Ad-EXs increased HBMEC cytotoxicity and permeability while reducing angiogenesis after H/R injury. Mechanistically, HG-Ad-EXs promoted oxidative stress through increased NOX2/4 and lipid peroxidation via elevated MDA/4-HNE and reduced GPX4 expression. Conclusions: Hyperglycemic Ad-EX triggered oxidative stress via NOX2/4 and lipid peroxidation via MDA/4HNE/GPX4, leading to impaired HBMEC functioning, which was exacerbated in the H/R injury condition.
- 1 September 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (9) , 896
Open AccessHyperglycemic Adipocyte-Derived Exosomes Cause Oxidative Stress and Lipid Peroxidation in Brain Microvascular Endothelial Cells
Background/Aims: Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia and is a risk factor for stroke. Our previous studies demonstrated that adipocyte-derived exosomes (Ad-EXs) mediate adipose–brain communication. This study investigated the effects of hyperglycemic subcutaneous and visceral Ad-EXs on brain microvascular endothelial cell (BMEC) dysfunction during ischemic injury. Hypothesis: Hyperglycemic Ad-EXs exacerbate stroke injury via inducing oxidative stress and lipid peroxidation in BMECs. Methods: EXs were isolated from primary human subcutaneous and visceral adipocytes cultured in normal glucose (NG): NG-S-Ad-EXs and NG-V-Ad-EXs, or high-glucose (HG, 25 mM) media: HG-S-Ad-EXs and HG-V-Ad-EXs by ultracentrifugation and characterized by a nanoparticle tracking analysis system. PKH26-labeled Ad-EXs were used to evaluate uptake mechanisms in human BMECs (HBMECs). Functional effects were assessed in hypoxia/reoxygenation (H/R)-injured HBMECs treated with different Ad-EXs. Oxidative stress and lipid peroxidation markers (NOX2/4, MDA, 4-HNE, and GPX4) were analyzed. Results: HG increased Ad-EX release from both adipocyte depots. HG-derived Ad-EXs increased HBMEC cytotoxicity and permeability while reducing angiogenesis after H/R injury. Mechanistically, HG-Ad-EXs promoted oxidative stress through increased NOX2/4 and lipid peroxidation via elevated MDA/4-HNE and reduced GPX4 expression. Conclusions: Hyperglycemic Ad-EX triggered oxidative stress via NOX2/4 and lipid peroxidation via MDA/4HNE/GPX4, leading to impaired HBMEC functioning, which was exacerbated in the H/R injury condition.
- Open Access
- 19 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9139
Mechanism of Regulation of NaCl Homeostasis in the Distal Colon During Obesity
Obesity is characterized by low-grade chronic inflammation, similar to the pathophysiology of inflammatory bowel disease (IBD) and colon cancer. IBD, which includes Crohn’s disease and ulcerative colitis, is becoming increasingly common in obese individuals. Our previous research documented that both IBD and obesity involve disrupted NaCl homeostasis in the small intestine. The present study investigated how obesity affects NaCl homeostasis in the distal colon, using the Zucker (Leprfa) rat as a genetic model of obesity. The functional and molecular alterations in NaCl homeostasis were evaluated through radioactive uptakes, RT-qPCR, and Western blot studies. We found a significant reduction in Cl absorption via Cl−/HCO3− exchanger, Downregulated in Adenoma (DRA) in the distal colon of obese rats compared to lean controls. This reduction was due to a decrease in the maximum transport capacity (Vmax) of DRA, with no change in the affinity of the exchanger for chloride. DRA mRNA and protein levels were also downregulated in obese animals. In contrast, Na absorption via Na+/H+ exchanger and its expression remained unchanged. These findings are the first to demonstrate that DRA is significantly impaired in the distal colon due to obesity. This suggests that net NaCl absorption in the distal colon is compromised in obesity, potentially increasing the risk for IBD and colon cancer.
- 19 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9139
Open AccessMechanism of Regulation of NaCl Homeostasis in the Distal Colon During Obesity
Obesity is characterized by low-grade chronic inflammation, similar to the pathophysiology of inflammatory bowel disease (IBD) and colon cancer. IBD, which includes Crohn’s disease and ulcerative colitis, is becoming increasingly common in obese individuals. Our previous research documented that both IBD and obesity involve disrupted NaCl homeostasis in the small intestine. The present study investigated how obesity affects NaCl homeostasis in the distal colon, using the Zucker (Leprfa) rat as a genetic model of obesity. The functional and molecular alterations in NaCl homeostasis were evaluated through radioactive uptakes, RT-qPCR, and Western blot studies. We found a significant reduction in Cl absorption via Cl−/HCO3− exchanger, Downregulated in Adenoma (DRA) in the distal colon of obese rats compared to lean controls. This reduction was due to a decrease in the maximum transport capacity (Vmax) of DRA, with no change in the affinity of the exchanger for chloride. DRA mRNA and protein levels were also downregulated in obese animals. In contrast, Na absorption via Na+/H+ exchanger and its expression remained unchanged. These findings are the first to demonstrate that DRA is significantly impaired in the distal colon due to obesity. This suggests that net NaCl absorption in the distal colon is compromised in obesity, potentially increasing the risk for IBD and colon cancer.
- Open Access
- 23 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7080
Gut Microbial Metabolites of Tryptophan Augment Enteroendocrine Cell Differentiation in Human Colonic Organoids: Therapeutic Potential for Dysregulated GLP1 Secretion in Obesity
Enteroendocrine cells (EECs) are specialized secretory cells in the gut epithelium that differentiate from intestinal stem cells (ISCs). Mature EECs secrete incretin hormones that stimulate pancreatic insulin secretion and regulate appetite. Decreased EEC numbers and impaired secretion of the incretin glucagon-like peptide-1 (GLP1) have been implicated in obesity-associated metabolic complications. Gut microbial metabolites of dietary tryptophan (TRP) were recently shown to modulate ISC proliferation and differentiation. However, their specific effects on EEC differentiation are not known. We hypothesized that the gut microbial metabolites of dietary tryptophan counteract impaired GLP1 production and function in obesity by stimulating EEC differentiation from ISCs. We utilized complementary models of human and rat intestines to determine the effects of obesity or TRP metabolites on EEC differentiation. EEC differentiation was assessed by the EEC marker chromogranin A (CHGA) levels in the intestinal mucosa of normal versus obese rats. The effects of TRP metabolites on EEC differentiation were determined in human intestinal organoids treated with indole, a primary TRP metabolite, or the culture supernatant of Lactobacillus acidophilus grown in TRP media (LA-CS-TRP). Our results showed that the mRNA and protein levels of CHGA, the EEC marker, were significantly decreased (~60%) in the intestinal mucosa of high-fat-diet-induced obese rat intestines. The expression of the transcription factors that direct the ISC differentiation towards the EEC lineage was also decreased in obesity. In human organoids, treatment with indole or LA-CS-TRP significantly increased (more than 2-fold) CHGA levels, which were blocked by the aryl hydrocarbon receptor (AhR) antagonist CH-223191. Thus, the stimulation of EEC differentiation by colonic microbial metabolites highlights a novel therapeutic role of TRP metabolites in obesity and associated metabolic disorders.
- 23 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7080
Open AccessGut Microbial Metabolites of Tryptophan Augment Enteroendocrine Cell Differentiation in Human Colonic Organoids: Therapeutic Potential for Dysregulated GLP1 Secretion in Obesity
Enteroendocrine cells (EECs) are specialized secretory cells in the gut epithelium that differentiate from intestinal stem cells (ISCs). Mature EECs secrete incretin hormones that stimulate pancreatic insulin secretion and regulate appetite. Decreased EEC numbers and impaired secretion of the incretin glucagon-like peptide-1 (GLP1) have been implicated in obesity-associated metabolic complications. Gut microbial metabolites of dietary tryptophan (TRP) were recently shown to modulate ISC proliferation and differentiation. However, their specific effects on EEC differentiation are not known. We hypothesized that the gut microbial metabolites of dietary tryptophan counteract impaired GLP1 production and function in obesity by stimulating EEC differentiation from ISCs. We utilized complementary models of human and rat intestines to determine the effects of obesity or TRP metabolites on EEC differentiation. EEC differentiation was assessed by the EEC marker chromogranin A (CHGA) levels in the intestinal mucosa of normal versus obese rats. The effects of TRP metabolites on EEC differentiation were determined in human intestinal organoids treated with indole, a primary TRP metabolite, or the culture supernatant of Lactobacillus acidophilus grown in TRP media (LA-CS-TRP). Our results showed that the mRNA and protein levels of CHGA, the EEC marker, were significantly decreased (~60%) in the intestinal mucosa of high-fat-diet-induced obese rat intestines. The expression of the transcription factors that direct the ISC differentiation towards the EEC lineage was also decreased in obesity. In human organoids, treatment with indole or LA-CS-TRP significantly increased (more than 2-fold) CHGA levels, which were blocked by the aryl hydrocarbon receptor (AhR) antagonist CH-223191. Thus, the stimulation of EEC differentiation by colonic microbial metabolites highlights a novel therapeutic role of TRP metabolites in obesity and associated metabolic disorders.
- Open Access
- 14 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (12) , 5713
Disease-Specific Novel Role of Growth Differentiation Factor 15 in Organ Fibrosis
Growth Differentiation Factor 15 (GDF15), also known as non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) or macrophage inhibitory cytokine 1 (MIC-1), is a stress- and inflammation-induced cytokine distantly related to the TGF-β superfamily. Its highly elevated levels showed close association with various pathological conditions, making it an emerging biomarker of disease prognosis. However, most GDF15-mediated effects under normal physiology and various pathological conditions are poorly understood. This is partly because the only known GDF15 receptor is exclusively localized in the brain, and how GDF15 functions peripherally is currently unknown. Mounting recent evidence has shown GDF15’s critical role in fibrosis in multiple organs, such as the liver, lung, and kidney. Evidence further suggests that it can either contribute to fibrosis by promoting inflammation and fibroblast activation or confer protective effects by modulating the immune response and mitigating fibrosis severity. Thus, the exact role of GDF15 in fibrosis can vary depending on the organ involved and the specific disease context. For example, increased GDF15 in idiopathic pulmonary fibrosis (IPF) promotes fibrosis via fibroblast activation and collagen deposition. Conversely, GDF15 might have a protective role in liver fibrosis, with decreased GDF15 levels causing increased fibrosis severity, while GDF15 treatment ameliorates fibrosis. Due to its close association with fibrosis, GDF15 is being investigated as a potential biomarker for disease severity and monitoring treatment response. However, further research unraveling its mechanisms of action is needed to explore the potential of GDF15 as a therapeutic target for treating fibrosis, either by modulating its expression or utilizing its immunomodulatory properties. This review marshals the limited studies addressing the recently appreciated differential role of GDF15 in regulating the fibrotic process in different organs. The review also discusses the aspects of further research needed to highlight GDF 15 as a novel predictor and therapeutic target for fibrosis in different organs.
- 14 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (12) , 5713
Open AccessDisease-Specific Novel Role of Growth Differentiation Factor 15 in Organ Fibrosis
Growth Differentiation Factor 15 (GDF15), also known as non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) or macrophage inhibitory cytokine 1 (MIC-1), is a stress- and inflammation-induced cytokine distantly related to the TGF-β superfamily. Its highly elevated levels showed close association with various pathological conditions, making it an emerging biomarker of disease prognosis. However, most GDF15-mediated effects under normal physiology and various pathological conditions are poorly understood. This is partly because the only known GDF15 receptor is exclusively localized in the brain, and how GDF15 functions peripherally is currently unknown. Mounting recent evidence has shown GDF15’s critical role in fibrosis in multiple organs, such as the liver, lung, and kidney. Evidence further suggests that it can either contribute to fibrosis by promoting inflammation and fibroblast activation or confer protective effects by modulating the immune response and mitigating fibrosis severity. Thus, the exact role of GDF15 in fibrosis can vary depending on the organ involved and the specific disease context. For example, increased GDF15 in idiopathic pulmonary fibrosis (IPF) promotes fibrosis via fibroblast activation and collagen deposition. Conversely, GDF15 might have a protective role in liver fibrosis, with decreased GDF15 levels causing increased fibrosis severity, while GDF15 treatment ameliorates fibrosis. Due to its close association with fibrosis, GDF15 is being investigated as a potential biomarker for disease severity and monitoring treatment response. However, further research unraveling its mechanisms of action is needed to explore the potential of GDF15 as a therapeutic target for treating fibrosis, either by modulating its expression or utilizing its immunomodulatory properties. This review marshals the limited studies addressing the recently appreciated differential role of GDF15 in regulating the fibrotic process in different organs. The review also discusses the aspects of further research needed to highlight GDF 15 as a novel predictor and therapeutic target for fibrosis in different organs.
- Open Access
- 26 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1058
A Simplified Method for the Isolation of Extracellular Vesicles from Probiotic Bacteria and Their Characterization
Probiotic bacteria are normal inhabitants of a healthy human gut, conferring multiple beneficial effects on the gut and beyond. Under various disease states, the abundance and diversity of beneficial bacteria are significantly decreased, a process called dysbiosis. Among the intra- and extracellular components of probiotics, the extracellular vesicles (EVs) secreted by them have recently garnered significant attention as potential mediators of probiotics’ effects on host health. Further, these nanosized particles that encapsulate a wide range of bioactive molecules (proteins, lipids, RNA, and DNA) are standing out as key factors that could mediate gut microbiota–host communication and confer ameliorating effects in experimental inflammatory, metabolic, and cardiovascular disease models. However, a standard protocol of EV isolation from probiotic bacteria, not varying from lab to lab, must be established to achieve consistency in the experimental results in these pre-clinical models. Our current study compared two commonly used methods for EV isolation from biological samples, ultracentrifugation and precipitation, to develop a standard protocol for isolating EVs from the probiotics Lactobacillus acidophilus (LA), a Gram-positive bacterium, and Escherichia coli Nissle (EcN), a Gram-negative bacterium. The ultracentrifugation method gave ~1.5-fold higher EV yield for both LA and EcN compared to the precipitation method. Further, EcN released a higher level of EVs compared to LA. EVs were quantified and characterized by nanoparticle-tracking analysis (NTA) and by measuring the specific surface biomarkers using Western blot. Here, we describe our standardized step-by-step protocol for isolating EVs from probiotic bacteria and their characterization.
- 26 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1058
Open AccessA Simplified Method for the Isolation of Extracellular Vesicles from Probiotic Bacteria and Their Characterization
Probiotic bacteria are normal inhabitants of a healthy human gut, conferring multiple beneficial effects on the gut and beyond. Under various disease states, the abundance and diversity of beneficial bacteria are significantly decreased, a process called dysbiosis. Among the intra- and extracellular components of probiotics, the extracellular vesicles (EVs) secreted by them have recently garnered significant attention as potential mediators of probiotics’ effects on host health. Further, these nanosized particles that encapsulate a wide range of bioactive molecules (proteins, lipids, RNA, and DNA) are standing out as key factors that could mediate gut microbiota–host communication and confer ameliorating effects in experimental inflammatory, metabolic, and cardiovascular disease models. However, a standard protocol of EV isolation from probiotic bacteria, not varying from lab to lab, must be established to achieve consistency in the experimental results in these pre-clinical models. Our current study compared two commonly used methods for EV isolation from biological samples, ultracentrifugation and precipitation, to develop a standard protocol for isolating EVs from the probiotics Lactobacillus acidophilus (LA), a Gram-positive bacterium, and Escherichia coli Nissle (EcN), a Gram-negative bacterium. The ultracentrifugation method gave ~1.5-fold higher EV yield for both LA and EcN compared to the precipitation method. Further, EcN released a higher level of EVs compared to LA. EVs were quantified and characterized by nanoparticle-tracking analysis (NTA) and by measuring the specific surface biomarkers using Western blot. Here, we describe our standardized step-by-step protocol for isolating EVs from probiotic bacteria and their characterization.
- Open Access
- 13 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (12) , 6537
Intestinal Epithelial Creatine Transporter SLC6A8 Dysregulation in Inflammation and in Response to Adherent Invasive E. coli Infection
Creatine transporter (CrT1) mediates cellular uptake of creatine (Cr), a nutrient pivotal in maintaining energy homeostasis in various tissues including intestinal epithelial cells (IECs). The impact of CrT1 deficiency on the pathogenesis of various psychiatric and neurological disorders has been extensively investigated. However, there are no studies on its regulation in IECs in health and disease. Current studies have determined differential expression of CrT1 along the length of the mammalian intestine and its dysregulation in inflammatory bowel disease (IBD)-associated inflammation and Adherent Invasive E. coli (AIEC) infection. CrT1 mRNA and protein levels in normal intestines and their alterations in inflammation and following AIEC infection were determined in vitro in model IECs (Caco-2/IEC-6) and in vivo in SAMP1/YitFc mice, a model of spontaneous ileitis resembling human IBD. CrT1 is differentially expressed in different regions of mammalian intestines with its highest expression in jejunum. In vitro, CrT1 function (Na+-dependent 14C-Cr uptake), expression and promoter activity significantly decreased following TNFα/IL1β treatments and AIEC infection. SAMP1 mice and ileal organoids generated from SAMP1 mice also showed decreased CrT1 mRNA and protein compared to AKR controls. Our studies suggest that Cr deficiency in IECs secondary to CrT1 dysregulation could be a key factor contributing to IBD pathogenesis.
- 13 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (12) , 6537
Open AccessIntestinal Epithelial Creatine Transporter SLC6A8 Dysregulation in Inflammation and in Response to Adherent Invasive E. coli Infection
Creatine transporter (CrT1) mediates cellular uptake of creatine (Cr), a nutrient pivotal in maintaining energy homeostasis in various tissues including intestinal epithelial cells (IECs). The impact of CrT1 deficiency on the pathogenesis of various psychiatric and neurological disorders has been extensively investigated. However, there are no studies on its regulation in IECs in health and disease. Current studies have determined differential expression of CrT1 along the length of the mammalian intestine and its dysregulation in inflammatory bowel disease (IBD)-associated inflammation and Adherent Invasive E. coli (AIEC) infection. CrT1 mRNA and protein levels in normal intestines and their alterations in inflammation and following AIEC infection were determined in vitro in model IECs (Caco-2/IEC-6) and in vivo in SAMP1/YitFc mice, a model of spontaneous ileitis resembling human IBD. CrT1 is differentially expressed in different regions of mammalian intestines with its highest expression in jejunum. In vitro, CrT1 function (Na+-dependent 14C-Cr uptake), expression and promoter activity significantly decreased following TNFα/IL1β treatments and AIEC infection. SAMP1 mice and ileal organoids generated from SAMP1 mice also showed decreased CrT1 mRNA and protein compared to AKR controls. Our studies suggest that Cr deficiency in IECs secondary to CrT1 dysregulation could be a key factor contributing to IBD pathogenesis.
- Open Access
- 9 August 2023
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 17, 1241418
Emerging therapeutic role of gut microbial extracellular vesicles in neurological disorders
Extracellular vesicles (EVs) serve as cell-to-cell and inter-organ communicators by conveying proteins and nucleic acids with regulatory functions. Emerging evidence shows that gut microbial-released EVs play a pivotal role in the gut-brain axis, bidirectional communication, and crosstalk between the gut and the brain. Increasing pre-clinical and clinical evidence suggests that gut bacteria-released EVs are capable of eliciting distinct signaling to the brain with the ability to cross the blood–brain barrier, exerting regulatory function on brain cells such as neurons, astrocytes, and microglia, via their abundant and diversified protein and nucleic acid cargo. Conversely, EVs derived from certain species of bacteria, particularly from gut commensals with probiotic properties, have recently been shown to confer distinct therapeutic effects on various neurological disorders. Thus, gut bacterial EVs may be both a cause of and therapy for neuropathological complications. This review marshals the basic, clinical, and translational studies that significantly contributed to our up-to-date knowledge of the therapeutic potential of gut microbial-derived EVs in treating neurological disorders, including strokes, Alzheimer’s and Parkinson’s disease, and dementia. The review also discusses the newer insights in recent studies focused on developing superior therapeutic microbial EVs via genetic manipulation and/or dietary intervention.
- 9 August 2023
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 17, 1241418
Open AccessEmerging therapeutic role of gut microbial extracellular vesicles in neurological disorders
Extracellular vesicles (EVs) serve as cell-to-cell and inter-organ communicators by conveying proteins and nucleic acids with regulatory functions. Emerging evidence shows that gut microbial-released EVs play a pivotal role in the gut-brain axis, bidirectional communication, and crosstalk between the gut and the brain. Increasing pre-clinical and clinical evidence suggests that gut bacteria-released EVs are capable of eliciting distinct signaling to the brain with the ability to cross the blood–brain barrier, exerting regulatory function on brain cells such as neurons, astrocytes, and microglia, via their abundant and diversified protein and nucleic acid cargo. Conversely, EVs derived from certain species of bacteria, particularly from gut commensals with probiotic properties, have recently been shown to confer distinct therapeutic effects on various neurological disorders. Thus, gut bacterial EVs may be both a cause of and therapy for neuropathological complications. This review marshals the basic, clinical, and translational studies that significantly contributed to our up-to-date knowledge of the therapeutic potential of gut microbial-derived EVs in treating neurological disorders, including strokes, Alzheimer’s and Parkinson’s disease, and dementia. The review also discusses the newer insights in recent studies focused on developing superior therapeutic microbial EVs via genetic manipulation and/or dietary intervention.
- Top Cited PapersOpen Access
The Influence of Alcohol Consumption on Intestinal Nutrient Absorption: A Comprehensive Review
Chronic alcohol use has been attributed to the development of malnutrition. This is in part due to the inhibitory effect of ethanol on the absorption of vital nutrients, including glucose, amino acids, lipids, water, vitamins, and minerals within the small intestine. Recent advances in research, along with new cutting-edge technologies, have advanced our understanding of the mechanism of ethanol’s effect on intestinal nutrient absorption at the brush border membrane (BBM) of the small intestine. However, further studies are needed to delineate how ethanol consumption could have an impact on altered nutrient absorption under various disease conditions. Current research has elucidated the relationship of alcohol consumption on glucose, glutamine, vitamins B1 (thiamine), B2 (riboflavin), B9 (folate), C (ascorbic acid), selenium, iron, and zinc absorption within the small intestine. We conducted systematic computerized searches in PubMed using the following keywords: (1) “Alcohol effects on nutrient transport”; (2) “Alcohol mediated malabsorption of nutrients”; (3) “Alcohol effects on small intestinal nutrient transport”; and (4) “Alcohol mediated malabsorption of nutrients in small intestine”. We included the relevant studies in this review. The main objective of this review is to marshal and analyze previously published research articles and discuss, in-depth, the understanding of ethanol’s effect in modulating absorption of vital macro and micronutrients in health and disease conditions. This could ultimately provide great insights in the development of new therapeutic strategies to combat malnutrition associated with alcohol consumption.
Top Cited PapersOpen AccessThe Influence of Alcohol Consumption on Intestinal Nutrient Absorption: A Comprehensive Review
Chronic alcohol use has been attributed to the development of malnutrition. This is in part due to the inhibitory effect of ethanol on the absorption of vital nutrients, including glucose, amino acids, lipids, water, vitamins, and minerals within the small intestine. Recent advances in research, along with new cutting-edge technologies, have advanced our understanding of the mechanism of ethanol’s effect on intestinal nutrient absorption at the brush border membrane (BBM) of the small intestine. However, further studies are needed to delineate how ethanol consumption could have an impact on altered nutrient absorption under various disease conditions. Current research has elucidated the relationship of alcohol consumption on glucose, glutamine, vitamins B1 (thiamine), B2 (riboflavin), B9 (folate), C (ascorbic acid), selenium, iron, and zinc absorption within the small intestine. We conducted systematic computerized searches in PubMed using the following keywords: (1) “Alcohol effects on nutrient transport”; (2) “Alcohol mediated malabsorption of nutrients”; (3) “Alcohol effects on small intestinal nutrient transport”; and (4) “Alcohol mediated malabsorption of nutrients in small intestine”. We included the relevant studies in this review. The main objective of this review is to marshal and analyze previously published research articles and discuss, in-depth, the understanding of ethanol’s effect in modulating absorption of vital macro and micronutrients in health and disease conditions. This could ultimately provide great insights in the development of new therapeutic strategies to combat malnutrition associated with alcohol consumption.
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1578: MOLECULAR MECHANISM OF INHIBITION OF NA-K-ATPASE ACTIVITY BY INDUCIBLE NITRIC OXIDE IN INTESTINAL EPITHELIAL CELLS.
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1578: MOLECULAR MECHANISM OF INHIBITION OF NA-K-ATPASE ACTIVITY BY INDUCIBLE NITRIC OXIDE IN INTESTINAL EPITHELIAL CELLS.